Abstract: The invention relates to manufacturing of fully dense strips, plates, sheets, and foils from titanium alloys, titanium metal matrix composites, titanium aluminides, and flat multilayer composites of said materials by direct powder rolling of blended powders followed by sintering. The resulting titanium alloy flat products have properties that meet or exceed the conventional ingot metallurgy alloys and are suitable for aerospace, automotive, sporting goods, and other applications. The process includes: (a) providing C.P.

Abstract: A method of fabricating a sputter target comprises: homogenously blending a plurality of powders including at least a first powder and a second powder. The first powder is comprised of chromium (Cr), cobalt (Co), ruthenium (Ru), nickel (Ni), or iron (Fe). The second powder is comprised of boron (B), carbon (C), a nitrogen (N)-containing material, a boride, a carbide, a nitride, a silicide, an oxygen (O)-containing material or an oxide. The second powder has a particle size of between 0.01 microns and 50 microns. The method further comprises: canning the blended plurality of powders to form a substantially non-segregated encapsulated powdered material mix; pressing the encapsulated powdered material mix to form a billet; and machining the billet to form a sputter target.

Abstract: The invention concerns a method of preparing products having a sintered density of above 7.3 g/cm3. This method comprises the steps of subjecting a water-atomised, stainless steel powder to HVC compaction with an uniaxial pressure movement with a ram speed of at least 2 m/s, and sintering the green body.

Abstract: Timepiece or jewelry part manufactured in an alloy containing at least 75% gold by weight, from 21% to 23% copper by weight, and from 1% to 4% platinum by weight.

Abstract: The present invention provides an effective method of inhibiting corrosion on metallic surfaces in contact with a fluid contained in an industrial system, which includes adding to such fluid an effective corrosion controlling amount of a phosphoglyceride compound, optionally with emulsified soybean oil.

Abstract: An apparatus and methods to produce synergistic mixtures (or combinations) of haloamines to control growth of microorganisms in aqueous systems are disclosed. The apparatus and methods to produce synergistic mixtures entails producing a batch quantity of a haloamine and converting part of the haloamine to a second haloamine species to form the synergistic mixture.

Abstract: The invention is directed to a syringe pump for the controlled addition of reagents to a chemical reaction. The pump has a reduced size for use as a cordless, hand-held laboratory device, and includes a driving mechanism for moving the plunger of a syringe along the syringe barrel, a means for sensing a physical property of the reaction mixture, and a logic control circuit. The driving mechanism includes a motor, a drive shaft, a drive block, and a sliding barrel clamp. The logic control circuit is programmable and controls the syringe pump based on predetermined parameters. The syringe pump adapts the delivery rate of reagent according to changes in physical properties of the reaction mixture such as pH and/or temperature, thus providing a high degree of automated control over a chemical reaction.

Abstract: The present invention provides a well-less filtration device that includes a pre-filter layer; a support layer; and at least one layer of solid phase extraction medium disposed between the pre-filter layer and the support layer. At least a portion of the pre-filter layer, support layer and solid phase extraction medium are ultrasonically welded together to form a pattern of filter cells and land areas with the land areas being disposed between the filter cells. The filter cells of the device may be arranged to conform to a standardized array format.

Abstract: A chip having a deaerating function and requiring no bonding or welding for forming a channel, and an apparatus and method for the reaction analysis are provided. The chip contains a first substrate, a second substrate having a liquid inlet and a liquid outlet, and an intermediate member having hydro-phobicity and air permeability and forming a channel between the first and second substrates. It is thereby possible to prevent mixing of air bubbles into the channel.

Abstract: A manifold for connecting external capillaries to the inlet and/or outlet ports of a microfluidic device for high pressure applications is provided. The fluid connector for coupling at least one fluid conduit to a corresponding port of a substrate that includes: (i) a manifold comprising one or more channels extending therethrough wherein each channel is at least partially threaded, (ii) one or more threaded ferrules each defining a bore extending therethrough with each ferrule supporting a fluid conduit wherein each ferrule is threaded into a channel of the manifold, (iii) a substrate having one or more ports on its upper surface wherein the substrate is positioned below the manifold so that the one or more ports is aligned with the one or more channels of the manifold, and (iv) means for applying an axial compressive force to the substrate to couple the one or more ports of the substrate to a corresponding proximal end of a fluid conduit.

Abstract: The system is based on a change in the intensity of evaporation caused by a chimney effect, modifying the flow of air that circulates through the environment apparatus in the surrounding area of the wick. It consists of using a casing (1) with slots (6) for the passage of air in its upper part. This is done in such a manner that said casing (1) can be used in isolation, thus attaining an apparatus that does not regulate the evaporation intensity, but that has a complementary part (7) joined to the upper part of said casing (1). This assembly, enabling free turning, has complementary slots (9), that determine a greater or lesser flow of air and the consequent regulation of the intensity of the evaporation, depending on the greater or lesser degree of opposition they have to the slots (6).

Abstract: The present invention provides a system for continuously and efficiently producing low concentrations of aqueous chlorine dioxide from a dilute continuous feed stream of aqueous chlorite.

Abstract: A batch reaction system for simultaneously conducting reactions in at least two separate reactors (CSTR reactors), is provided wherein the at least two batch reactors, containing mixing means and a fluid inlet, a fluid feed common conduit is present for feed fluid to the reactors, which is connected to the inlet of each reactor of a fluid inlet conduits, and further includes a fluid discharge common conduit which is connected to the outlet of each reactor wherein in each fluid inlet conduit and/or in each fluid outlet conduit a non-return valve is arranged to prevent contamination but can provide simultaneous reactions wherein the reactors can be easily isolated from one another during reaction.

Abstract: This invention relates to a container having at least one inlet and/or outlet and containing at least two different solids arranged in layers as well as the use of said container for preparing a dialysate. In particular, a flexible bag is described, having three layers of different solids, where the middle layer consists of a solid which is compatible with the two adjacent layers and thus forms a separating layer between the two other layers. The layers are secured in place during shipping by vacuum packing.

Abstract: A process reduces SOx emissions in a flue gas stream by adding a wet collector plate section to an existing electrostatic precipitator (ESP) or by converting the last field of an existing ESP to wet operation. To achieve the conversion, the last field or fields of an existing dry ESP are removed and replaced with components made from materials suitable for operation in a wet environment. After the ESP contains wet operation, ammonia is added to the flue gas stream while it is progressing through the collection plates in the ESP.

Abstract: The present invention provides an annealed wafer which has a wafer surface layer serving as a device fabricating region and having an excellent oxide film dielectric breakdown characteristic, and a wafer bulk layer in which oxide precipitates are present at a high density at the stage before the wafer is loaded into the device fabrication processes to give an excellent IG capability, and a method for manufacturing the annealed wafer. The present invention is directed to an annealed wafer obtained by performing heat treatment on a silicon wafer manufactured from a silicon single crystal grown by the Czochralski method, wherein a good chip yield of an oxide film dielectric breakdown characteristic in a region having at least a depth of up to 5 ?m from a wafer surface is 95% or more, and a density of oxide precipitates detectable in the wafer bulk and each having a size not smaller than a size showing a gettering capability is not less than 1×109/cm3.

Abstract: The invention provides a process for production of carbon nanotubes whereby a laminate prepared by alternating lamination of a metal catalyst and a material other than the metal catalyst is cut to expose the laminated structure, and carbon nanotubes are grown on the metal catalyst at the cut surface of the laminate. The process results in high-quality carbon nanotubes, with minimized bundle growth, which are each individually and independently arranged in a highly precise manner at prescribed locations. The invention also provides a carbon nanotube production process comprising a step of preparing a substrate which is inclined in one or two dimensions from a specific highly symmetrical crystal orientation and vapor depositing a metal catalyst along the atomic steps appearing on the surface of the substrate, and a step of growing the carbon nanotubes by chemical vapor deposition (CVD) using the metal catalyst as nuclei.

Abstract: A process for the production of a fluorinated organic compound, characterized by fluorinating an organic compound having a hydrogen atoms using IF5; and a novel fluorination process for fluorinating an organic compound having a hydrogen atoms by using a fluorinating agent containing IF5 and at least one member selected from the group consisting of acids, bases, salts and additives.

Abstract: Recovering sulfur from a gas stream containing hydrogen sulfide by oxidizing the gas stream to convert the hydrogen sulfide in the gas stream to sulfur oxide, and thus form a sulfur oxide enriched gas stream. The sulfur oxide enriched gas stream is contacted with a solid, sulfation resistant adsorbent bed at relatively low temperatures to extract the sulfur oxides and retain them as sulfur compounds, thus forming a sulfur oxide depleted gas stream. The adsorbent bed is then contacted with an inert or reducing gas stream to reduce the retained sulfur compounds to sulfur and/or sulfur dioxide and thereby form an enriched sulfur and/or sulfur dioxide bearing stream. The elemental sulfur is recovered and/or the sulfur dioxide bearing stream may be recycled to the Claus unit for further conversion.

Abstract: Described is a multi drug multiligand conjugate for targeted drug delivery. The MDML conjugate contains a plurality of tripartite molecules linked to a central scaffold moiety, with each tripartite molecule comprising a targeting molecule, a therapeutic agent and a scaffold binding element. The MDML conjugate allows for more efficient delivery of therapeutic agents to the cells resulting in enhanced therapeutic efficiency. A model MDL conjugate is disclosed as well as method for the synthesis of the model conjugate.

Abstract: Amyloid-targeting imaging agents such as radiolabeled amyloid targeting molecules and amyloid targeting molecule-chelator conjugates for imaging, e.g., amyloid plaques in vivo, and/or for the treatment of amyloidosis disorders. The invention provides amyloid-targeting imaging agents that are useful for imaging sites of amyloid disease. Imaging agents of the invention are capable of binding specifically to amyloid plaques, as an aid in diagnosis and/or early treatment of amyloidosis disorders.

Abstract: The invention relates to propellant gas formulations containing suspensions of the crystalline monohydrate of (1?,2?,4?,5?,7?)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.

Abstract: The invention relates to cosmetic formulations containing dihydroxy-acetone and a topical support in addition to one or several compounds selected from the compounds of formulae (Ia) and (Ib), the physiologically acceptable salts of compounds of formulae (Ia) and (Ib), and the stereoisomeric forms of formulae (Ia) and (Ib), wherein R1, R2, R3, R4 and n have the meanings cited in Claim 1. The cosmetic formulations are characterized in that the UV-A protective effect of dihydroxyacetone is increased.

Abstract: Disclosed is a natural sunscreen composition comprising extracts of Hedychium spicatum and/or Alpinia galanga containing active sunscreen agents, the sunscreen composition devised to protect the skin from the harmful effects of short wavelength UV B rays and long wavelength UV A rays.

Abstract: Disclosed is the use of the compounds of formula wherein A is a radical of formula R1 and R5 independently from each other are hydrogen; C1-C18alkyl; or C6-C12aryl; R2, R3 and R4 independently from each other are hydrogen; or a radical of formula wherein, in formula (1a), at least one of the radicals R2, R3 and R4 are a radical of formula (1c); R6, R7, R8, R9 and R10 independently from each other are hydrogen; hydroxy; halogen; C1-C18alkyl; C1-C18alkoxy; C6-C12aryl; biphenylyl; C6-C12aryloxy; C1-C18alkylthio; carboxy; —COOM; C1-C18-alkylcarboxyl; aminocarbonyl; or mono- or di-C1-C18alkylamino; C1-C10acylamino; —COOH; M is an alkali metal ion; x is 1 or 2; and y is a number from 2 to 10; for the protection of human and animal hair and skin against the damaging effect of UV radiation. The compounds of formula (1) are high effective UV absorbers for cosmetic formulations aund can be—depending on their physical properties be used in micronized or soluble form.

Abstract: A zirconium-free aluminum salt which: (a) has an aluminum to chloride molar ratio in the range of 0.5-2.5:1; (b) comprises a nitrogen containing buffering material in an amount such that the ratio of nitrogen containing material to aluminum is the range of 0.05-0.26:1, and which nitrogen containing material is selected from the group consisting of a nitrogen containing buffering material of formula where n is a number in the range of 1-20, and each of R1, R2, and R3 is independently selected from the group consisting of hydrogen, methyl and ethyl; and (c) the salt has a pH in the range of 2-4 at a concentration of 15%; wherein the salt is free of any other halide scavenging material and has a value of at least 0.50 for the ratio calculated as: area of Peak 5/total area under Peak 2+Peak 3+Peak 4+Peak 5.

Abstract: Compositions, and methods for using compositions, comprising at least one silicone, at least one compound comprising at least one ester group, and at least one copolymer. In an embodiment, the inventive compositions do not comprise any volatile solvents. Compositions comprising at least one encapsulated pigment, wherein the at least one encapsulated pigment is dispersed in at least one silicone are also disclosed.

Abstract: A powder mixture for mixing with water to form a gel for a gel/air freshener system includes a fragrance, amorphous fumed silica, a super-absorbent polymer and a surfactant. The mixture can also include a dye and a deodorizer, which may replace a portion of the fragrance or be in combination with the fragrance.

Abstract: The present invention relates to an amphiphilic block copolymer of a hydrophilic block and a hydrophobic block with a terminal hydroxyl group wherein the terminal hydroxyl group of the hydrophobic bock is substituted with a tocopherol or cholesterol group. It also relates to polymeric compositions capable of forming stable micelles in an aqueous solution, comprising the amphiphilic block copolymer and a polylactic acid derivative wherein one or more ends of the polylactic acid are covalently bound to at least one carboxyl group.

Abstract: Human interleukin-18 (IL-18) polypeptides and substitution mutants thereof were conjugated to water-soluble polymers at specific sites on the human IL-18 protein. These conjugated human IL-18 and substitution mutants thereof retain biological activity. These conjugated cytokines demonstrate enhanced and unexpected biological properties when compared to the corresponding unconjugated cytokines.

Abstract: The present invention relates to an amino acid-modified human interferon alpha isoform having at least one of the Asn-Xaa-Ser/Thr (N-X-S/T) sequence formed at a specific site so that glycosylation takes place at this site and a gene encoding the same, an expression vector comprising the gene, and a method for producing glycosylated human interferon alpha isoform by transforming or transfecting an eukaryotic cell with the expression vector, culturing the transfected or transformed cell and isolating the glycosylated human interferon alpha isoform from the culture, the glycosylated human interferon alpha isoform produced therefrom and a pharmaceutical composition comprising the same.

Abstract: A method of manufacturing a tissue matrix for implantation into a patient is disclosed. The method sets forth collecting embryonic stem cells from a placenta which has been treated to remove residual cord blood and seeding the collected stem cells onto or into a tissue matrix. The seeded tissue matrix is then implanted on or into a patient. The seeded tissue matrix made by the method of the present invention is also disclosed.

Abstract: The present invention provides compositions and methods of using embryonic-like stem cells that originate from a post-partum placenta with conventional cord blood compositions or other stem or progenitor cells. The embryonic-like stem cells can be used alone or in a mixture with other stem cell populations. In accordance with the present invention, the embryonic-like stem cells may be mixed with other stem cell populations, including but not limited to, umbilical cord blood, fetal and neonatal hematopoietic stem cells and progenitor cells, human stem cells and progenitor cells derived from bone marrow. The embryonic-like stem cells and the mixed populations of embryonic-like stem cells and stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses.

Abstract: Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating viral infection.

Abstract: Novel packaging cell lines which produce recombinant retrovirus, free of detectable helper-virus are disclosed. Also disclosed are methods of making the cell lines and methods of producing recombinant retroviruses from the cell lines. Retroviruses produced by the cell lines include lentiviruses, such as HIV, capable of transfering heterologous DNA to a wide range of non-dividing cells. The packaging cells contain at least three vectors which collectively encode retroviral gag, pol, and env proteins, wherein the gag and pol genes are separated, in part, onto two or more different vectors. This is made possible by fusing Vpr or Vpx to pol proteins separated from gag so that the proteins are targeted to assembling virions. Among other advantages, the packaging cells provide the benefit of increased safety when used in human gene therapy by virtually eliminating the possibility of molecular recombination leading to production of replication competent helper virus.

Abstract: Frozen and lyophilized compositions for a metalloproteinase fibrinolytic agent (fibrolase or NAT), a method for preparing the lyophilized composition, and a kit and method for reconstituting the lyophilized composition are described herein.

Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.

Abstract: The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.

Abstract: The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting ?5?1 integrin in the tissue with an agent that interferes with the specific binding of ?5?1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds ?5?1 integrin, and detecting specific binding of the agent to ?5?1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual; methods of reducing or inhibiting angio genesis in a tissue in an individual; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of ?5?1 integrin to a ligand in a tissue associated with the pathological condition.

Abstract: Targeting molecules for use in delivering biological agents to epithelial tissue are disclosed. Upon delivery, the biological agent(s) may remain within an epithelial cell or may undergo transepithelial transport via transcytosis. The targeting molecules may be used, for example, for the delivery of therapeutic agents.

Abstract: Anti-thrombotic agents containing humanized antibodies which bind to von Willebrand factor.

Abstract: The invention provides antigenic peptides derived from MAGE polypeptides and presented by HLA-B37 molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.

Abstract: The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.

Abstract: The present invention is directed to the induction and characterization of a humoral immune response targeting “entry-relevant” gp41 structures. In its broadest aspect, the present invention is directed to methods of raising a neutralizing antibody response to a broad spectrum of HIV strains and isolates. The present invention targets particular molecular conformations or structures that occur at the cell surface of HIV during viral entry into host cells. Such a humoral response can be generated in vivo as a prophylactic measure in individuals to reduce or inhibit the ability of HIV to infect uninfected cells in the individual's body. Such a response can also be employed to raise antibodies against “entry relevant” gp41 structures. These antibodies can be employed for therapeutic uses, and as tools for further illuminating the mechanism of HIV cell entry.

Abstract: The invention discloses the Moraxella catarrhalis outer membrane protein polypeptide and polypeptides derived therefrom (collectively “OMP21”), nucleotide sequences encoding said OMP21, and antibodies that specifically bind OMP21. Also disclosed are pharmaceutical compositions including prophylactic or therapeutic compositions, which may be immunogenic compositions including vaccines, comprising OMP21, antibodies thereto or nucleotides encoding same. The invention additionally discloses methods of inducing an immune response to M. catarrhalis and OMP21 in an animal, preferably a human, methods of treating and methods of diagnosing Moraxella infections in an animal, preferably a human, and kits therefor.

Abstract: The present invention is directed to the generation and use of recombinant rotavirus fusion proteins as immunogens to produce a protective immune response from immunized individuals. In one embodiment, the present invention contemplates a recombinant rotavirus fusion protein vaccine composition comprising a rotavirus subunit protein or immunogenic fragment thereof, and an adjuvant in combination with the recombinant rotavirus subunit fusion protein. In one aspect of this embodiment, the recombinant rotavirus fusion protein comprises a rotavirus subunit protein and a fusion partner protein in genetic association with the rotavirus subunit protein, wherein the fusion partner protein does not interfere with expression and immunogenicity of the rotavirus subunit protein, the fusion partner protein prevents complex formation by the rotavirus subunit protein, and the fusion partner protein facilitates purification of the recombinant rotavirus fusion protein.

Abstract: Compositions and methods for treating osteoporosis, the formation of osteoeclasts, and/or for the suppression of decreasing spongy bone density. Example methods include administering Cordyceps sinensis or its processed product.

Abstract: The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can interact with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occupancy of co-receptor present on the cell, for example. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CCR5 and CXCR4 sequences.

Abstract: The subject invention pertains to novel methods and compositions for protecting cats from infection by a broad range of FIV strains using a multi-subtype FIV vaccine. Multi-subtype FIV vaccines comprising either cell free whole virus or cell lines infected with viruses are described. Methods for vaccinating cats with the subject vaccine compositions are also described. Cats vaccinated according to the methods and compositions of the subject invention exhibit protective humoral and cellular immune responses to FIV when challenged with homologous or heterologous strains of FIV. The subject invention also pertains to novel feline cell lines that are susceptible to infection by FIV and their methods of use.

Abstract: The present invention relates to fusion proteins containing at least two Mycobacterium species antigens. In particular, it relates to nucleic acids encoding fusion proteins that include two or more individual M. tuberculosis antigens, which increase serological sensitivity of sera from individuals infected with tuberculosis, and methods for their use in the diagnosis, treatment, and prevention of tuberculosis infection.